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Biopsy analysis could be an ideal outcome but is sometimes ne-
glected by patients and review ethical boards; the use of advanced
MRI techniques as surrogate (T2 and dGEMRIC) is proposed. Dif-
ﬁculties to screen and determine eligibility of appropriate patients:
Preoperatory diagnosis of focal cartilage lesions is difﬁcult; until
an arthroscopy is performed there’s no certainty about the nature
of the lesion, as well as of concomitant pathologies. Potential
problems arising from concomitant surgeries (ACL reconstruc-
tions, multiple lesions) could become confounding factors. Patient
enrolment is a true challenge. Standardization of treatment: A high
degree of compliance with standardization of actions before, dur-
ing and after the surgical procedure is difﬁcult to obtain, especially
especially for an international trial. Physiotherapy is a critical point
and a consensus regarding this aspect of cartilage repair has not
been achieved. Need to design a trial which meets expectations of
third party payers: Due to needs in terms of regulatory and statisti-
cal compliance the indications have to be limited (size/depth of the
treated lesions, symptoms, patient age range), or the number of
patients needed to demonstrate if there are statistical differences
among groups will increase. Difﬁculty to show potential clinical
beneﬁt in the long term is another issue (12 months vs longer
and more costly trials). Third party payers are expecting evidence
that there’s a long lasting improvement. A 12 month interim anal-
ysis is being conducted on a subset of 41 patients after 1 year
postop. A similar analysis at 6 months suggested evidence of a
positive effect of BST-CarGel® on cartilage quantity/quality by MRI
compared to control group. No major safety issues occurred.
Conclusions: Trials for study of cartilage repair represent a true
challenge for basic researchers, clinicians, industry and for reg-
ulatory bodies. This study represents an important step toward
developing evidence-based treatment algorithms for cartilage re-
pair as well as for the identiﬁcation of the diverse hurdles that
those trials may represent. It also shows that the use of new
tissue structure as a primary endpoint, relying on advanced MRI
techniques is feasible.
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Purpose: To characterize the incidence and severity of gastroin-
testinal (GI) treatment-emergent adverse events (TEAEs) associ-
ated with analgesic treatment with tapentadol ER or oxycodone
CR in patients with moderate to severe chronic osteoarthritis knee
pain.
Abstract 334 – Table 1. Incidence and Severity of Selected Gastrointestinal TEAEs
TEAE, n (%) Placebo (n=337) Tapentadol ER (n=344) Oxycodone CR (n=342)
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
All Gastrointestinal TEAEs 50 (56.8) 33 (37.5) 5 (5.7) 82 (55.4) 55 (37.2) 11 (7.4) 97 (42.2) 114 (49.6) 19 (8.3)
Nausea 14 (60.9) 7 (30.4) 2 (8.7) 48 (64.9) 21 (28.4) 5 (6.8) 59 (47.2) 54 (43.2) 12 (9.6)
Vomiting 4 (36.4) 4 (36.4) 3 (27.3) 11 (61.1) 6 (33.3) 1 (5.6) 28 (45.9) 30 (49.2) 3 (4.9)
Constipation 11 (50.0) 11 (50.0) 0 40 (61.6) 23 (35.4) 2 (3.1) 65 (51.6) 54 (42.9) 7 (5.6)
TEAE, treatment-emergent adverse event; ER, extended release; CR, controlled release.
Methods: In a randomized, double-blind, 15-week phase 3 trial,
patients with moderate to severe chronic osteoarthritis knee pain
received controlled, adjustable bid doses of tapentadol ER (100-
250 mg), oxycodone HCl CR (20-50 mg), or placebo over a 12-
week maintenance period, preceded by a 3-week titration period
to establish an optimal therapeutic dose. Efﬁcacy was assessed
using the change from baseline in average pain intensity over the
12-week maintenance period using the last observation carried
forward to impute missing values. The incidence and severity of
TEAEs were monitored over the 15-week treatment period.
Results: The intent-to-treat population included 1,023 patients.
Compared with placebo, tapentadol ER and oxycodone CR signif-
icantly reduced average pain intensity over the 12-week mainte-
nance period (least squares mean difference from placebo [stan-
dard error of the mean]: tapentadol ER, -0.7 [0.17], P<0.001;
oxycodone CR, -0.3 [0.17], P=0.049). The overall incidence of
TEAEs was 61.1%, 75.9%, and 87.4% in the placebo, tapentadol
ER, and oxycodone CR groups, respectively. The incidence of GI
TEAEs was 26.1% in the placebo group, 43.0% in the tapentadol
ER group, and 67.3% in the oxycodone CR group. Most TEAEs
were of mild to moderate intensity. Patients in the tapentadol ER
group reported lower incidences of GI TEAEs of moderate and se-
vere intensity than patients in the oxycodone CR group (Table). GI
TEAEs led to study discontinuation in 1.8% of the placebo group,
7.3% of the tapentadol ER group, and 26.9% of the oxycodone
CR group.
Conclusions: Tapentadol ER (100-250 mg bid) was associated
with numerically lower incidences of both moderate and severe GI
TEAEs and GI TEAEs leading to discontinuation compared with
oxycodone HCl CR (20-50 mg bid).
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Purpose: The purposes of the study were: (1) to examine the
relationship of regional adiposity with knee extensor strength,
pain, and physical function in older adults with knee osteoarthritis
(OA); (2) to investigate the association of knee extensor strength
with chair rise time, pain, and physical function; and (3) to explore
the relationship of leg extensor power with chair rise time and
4-meter walking speed.
Methods: 34 older adults with knee OA (65% female, mean age
= 71 yrs) were enrolled in the Strength Training in ARthritis Trial
(START) pilot study. Knee extensor strength was measured for the
most affected limb using a Kin-Com 125E Isokinetic Dynamometer
set at a speed of 30 deg/s. Leg extensor power (work done per
unit time) was assessed using a Nottingham Power Rig. Measures
of regional adiposity, percent lower extremity and trunk fat, were
obtained via a DXA scan. Chair rise time and 4-meter walking
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speed were obtained using the Short Physical Performance Bat-
tery (SPPB) test. Pain and physical function were measured using
the WOMAC. Pearson partial correlations and linear regression
analyses adjusted for age, sex, and BMI were used to examine
the relationships among the variables of interest.
Results: A lower percent lower extremity fat (thigh + leg) was sig-
niﬁcantly associated with reduced pain (r=0.54; p=0.02), greater
physical function (r=0.66; p=0.003), and higher knee extensor
strength (r=-0.58, p=0.01). No signiﬁcant associations were found
between percent trunk fat and these measures. Greater knee ex-
tensor strength was also signiﬁcantly associated with reduced pain
(r=-0.42; p=0.02) and greater physical function (r=-0.46; p=0.01).
In addition, higher leg extensor power was signiﬁcantly associated
with faster chair rise time (r=-0.76; p=0.001) and walking speed
(r=0.54; p=0.03).
Conclusions: These results suggest that lower extremity fat, but
not trunk fat, and weak knee extensor strength and power may play
important roles in the increased pain and poor function common in
older adults with knee OA. Improving knee extensor strength and
reducing thigh fat may provide long-term improvements in pain
and function.
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Purpose: To evaluate the effects of analgesic treatment with
tapentadol extended release (ER) on health-related outcomes in
patients with moderate to severe chronic osteoarthritis knee pain
based on the EuroQol-5 Dimension (EQ-5D) and Western On-
tario and MacMaster Universities Osteoarthritis Index (WOMAC)
questionnaires.
Methods: In this double-blind phase 3 trial, patients randomized
in a 1:1:1 ratio received controlled, adjustable bid doses of tapen-
tadol ER (100-250 mg), oxycodone HCl controlled release (CR;
20-50 mg), or placebo over a 12-week maintenance period, pre-
ceded by a 3-week titration period. Patients completed EQ-5D
(evaluates mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) and WOMAC (evaluates pain, disability, and
joint stiffness) questionnaires at baseline and at speciﬁed study
visits.
Results: Of 1,030 patients who were randomized, 1,023 patients
were evaluable for efﬁcacy. At endpoint, the change from base-
line in the EQ-5D health status index was signiﬁcantly greater
with tapentadol ER than with oxycodone CR or placebo, indicat-
ing a greater improvement in health status (least squares mean
difference [LSMD] between tapentadol ER and oxycodone CR,
0.1 [95% conﬁdence interval (CI), 0.03 to 0.10; P<0.001]; LSMD
between tapentadol ER and placebo, 0.1 [95% CI, 0.02 to 0.09;
P=0.004]). Differences between oxycodone CR and placebo were
not statistically signiﬁcant (LSMD, -0.0 [95% CI, -0.05 to 0.02;
P=0.449]). At endpoint, mean changes in WOMAC global scores
were signiﬁcantly improved from baseline for both tapentadol ER
and oxycodone CR compared with placebo (LSMD vs placebo for
tapentadol ER, -0.2 [95% CI, -0.36 to -0.06; P=0.005]; LSMD vs
placebo for oxycodone CR, -0.2 [95% CI, -0.34 to -0.01; P=0.038]).
Treatment-emergent adverse events occurred in 61.1%, 75.9%,
and 87.4% of patients in the placebo (n=337), tapentadol ER
(n=344), and oxycodone CR (n=342) groups, respectively.
Conclusions: In patients with chronic osteoarthritis knee pain,
tapentadol ER (100-250 mg bid) signiﬁcantly improved the EQ-5D
health status index compared with placebo and oxycodone HCl CR
(20-50 mg bid), and both active treatments signiﬁcantly improved
WOMAC scores compared with placebo.
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Purpose: To evaluate patient- and physician-reported global as-
sessments of study medication and changes in health functional
status in a 1-year study of tapentadol extended release (ER) and
oxycodone controlled release (CR) for relief of moderate to severe
chronic low back pain or osteoarthritis pain.
Methods: Patients were randomized in a 4:1 ratio to receive
controlled, adjustable, bid doses of tapentadol ER (100-250 mg) or
oxycodone HCl CR (20-50 mg) for up to 1 year in this open-label
safety study. Overall effectiveness was assessed with separate
patient and physician global assessments of study medication (0
= “poor” to 4 = “excellent”) and the EuroQol 5 Dimension (EQ-5D)
questionnaire evaluating health functional status. Patients rated
each dimension (mobility, usual activities, pain/discomfort, self-
care, and anxiety/depression) of the EQ-5D on 3 levels, from
“no problems” to “extreme problems.” No statistical comparisons
between tapentadol ER and oxycodone CR were performed.
Results: Patients who received at least 1 dose of study medica-
tion (n = 1,117) were included in the safety analysis set; 1,095
of these patients were included in the efﬁcacy analysis set. Ad-
verse events led to study discontinuation in 22.7% of patients
in the tapentadol ER group and 36.8% of patients in the oxy-
codone CR group. At study endpoint, 75.1% (616/820) and 72.3%
(128/177) of patients treated with tapentadol ER and oxycodone
CR, respectively, rated their medication as “excellent,” “very good,”
or “good”; global physician rating results were similar (77.3%
[635/821] and 72.3% [128/177], respectively). Both groups showed
improvements in EQ-5D, as demonstrated by positive changes in
health status index. The mean (standard error of the mean [SEM])
change from baseline to study endpoint in health status index was
0.2 (0.01) for tapentadol ER and 0.2 (0.03) for oxycodone CR.
Higher percentages of patients receiving tapentadol ER than oxy-
codone CR reported “no problems” in mobility (42.6% vs 32.2%),
usual activities (38.7% vs 28.2%), and pain/discomfort (15.7% vs
8.7%) at study endpoint. The percentage of patients reporting “no
problems” in the remaining 2 dimensions of self-care (75.0% vs
73.2%) and anxiety/depression (60.7% vs 61.1%) were similar in
the tapentadol ER and oxycodone CR groups, respectively.
Conclusions: Long-term treatment with tapentadol ER (100-250
mg bid) improved physical functioning and was effective and well
tolerated for up to 1 year for relief of moderate to severe chronic
pain.
